Evidence map›Paper›PMID 24307586›Full record

ArticleJournal of virology2014

De novo prion aggregates trigger autophagy in skeletal muscle.

Shivanjali Joshi-Barr, Cyrus Bett, Wei-Chieh Chiang, Margarita Trejo, Hans H Goebel, Beata Sikorska, Pawel Liberski, Alex Raeber, Jonathan H Lin, Eliezer Masliah and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Excess PrPNature communications · 2023
    Article
  2. Article
  3. Article
  4. Autophagy pathways in the treatment of prion diseases.Current opinion in pharmacology · 2019
    Review
  5. Review
  6. The frequency of yeast [Microbial cell (Graz, Austria) · 2017
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Shivanjali Joshi-BarrDepartment of Pathology, School of Medicine, University of California, San Diego, La Jolla, California, USA.
Cyrus Bett
Wei-Chieh Chiang
Margarita Trejo
Hans H Goebel
Beata Sikorska
Pawel Liberski
Alex Raeber
Jonathan H Lin
Eliezer Masliah
Christina J Sigurdson
University of California, San Diego · USMedical University of Lodz · PLUniversity Medical Center of the Johannes Gutenberg University Mainz · DEUniversity of California, Davis · US

Funding

Mechanisms of Prion Aggregation and Species BarriersR01NS069566 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ESKO, JEFFREY D, RAVITS, JOHN · 2011 to 2025
$5.7M
Mechanisms of Prion SpreadR01NS076896 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIGURDSON, CHRISTINA · 2012 to 2021
$3.4M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
Clearance Pathways in the CNS in Aging and HIVR01AG043384 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DESPLATS, PAULA ALEJANDRA · 2012 to 2016
$1.9M
Endoplasmic Reticulum Stress in Retinal DegenerationR01EY020846 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LIN, JONATHAN · 2010 to 2014
$1.9M
NEI NIH HHS EY020846NEI NIH HHS R01 EY020846NIAID NIH HHS U54AI0359NIA NIH HHS R01 AG043384NIA NIH HHS R37 AG018440NINDS NIH HHS NS069566NINDS NIH HHS NS076896NINDS NIH HHS R01 NS069566NINDS NIH HHS R01 NS076896
6 · The paper itself

Abstract

In certain sporadic, familial, and infectious prion diseases, the prion protein misfolds and aggregates in skeletal muscle in addition to the brain and spinal cord. In myocytes, prion aggregates accumulate intracellularly, yet little is known about clearance pathways. Here we investigated the clearance of prion aggregates in muscle of transgenic mice that develop prion disease de novo. In addition to neurodegeneration, aged mice developed a degenerative myopathy, with scattered myocytes containing ubiquitinated, intracellular prion inclusions that were adjacent to myocytes lacking inclusions. Myocytes also showed elevated levels of the endoplasmic reticulum chaperone Grp78/BiP, suggestive of impaired protein degradation and endoplasmic reticulum stress. Additionally, autophagy was induced, as indicated by increased levels of beclin-1 and LC3-II. In C2C12 myoblasts, inhibition of autophagosome maturation or lysosomal degradation led to enhanced prion aggregation, consistent with a role for autophagy in prion aggregate clearance. Taken together, these findings suggest that the induction of autophagy may be a central strategy for prion aggregate clearance in myocytes. IMPORTANCE In prion diseases, the prion protein misfolds and aggregates in the central nervous system and sometimes in other organs, including muscle, yet the cellular pathways of prion aggregate clearance are unclear. Here we investigated the clearance of prion aggregates in the muscle of a transgenic mouse model that develops profound muscle degeneration. We found that endoplasmic reticulum stress pathways were activated and that autophagy was induced. Blocking of autophagic degradation in cell culture models led to an accumulation of aggregated prion protein. Collectively, these findings suggest that autophagy has an instrumental role in prion protein clearance.

Indexed as

AnimalsAutophagyBlotting, WesternDNA PrimersEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsImmunohistochemistryMiceMice, TransgenicMuscle CellsMuscle, SkeletalPolymerase Chain ReactionPrion DiseasesDNA PrimersEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHspa5 protein, mouse

Identifiers

PMID24307586
PMCPMC3911572
OpenAlexW1964689729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.